FDA’s Off-Label Reprint Guidance Is Unlikely To Clarify Anything Very Soon
Executive Summary
Companies hoping that the end of the comment period for FDA's draft guidance on "good reprint practices" will swiftly produce a final roadmap should probably not hold their breath
You may also be interested in...
Reprinting FDAMA Approach: Waxman Urges FDA Review Of Off-Label Articles
Rep. Henry Waxman, D-Calif., is pushing FDA to require companies to submit reprints of journal articles on off-label use before providing them to practitioners, should the agency go forward with guidance permitting off-label promotion
Reprinting FDAMA Approach: Waxman Urges FDA Review Of Off-Label Articles
Rep. Henry Waxman, D-Calif., is pushing FDA to require companies to submit reprints of journal articles on off-label use before providing them to practitioners, should the agency go forward with guidance permitting off-label promotion
GlaxoSmithKline Hires Former FDA Top Lawyer Dan Troy As General Counsel
Former FDA Chief Counsel Daniel Troy will once again be leading a team of lawyers with a drug regulatory focus